NCT05042219 Effects of Pulmonary Diseases and Their Treatment on Cardiac Function
| NCT ID | NCT05042219 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ayham Daher |
| Condition | COPD |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2022-06-01 |
| Primary Completion | 2026-09-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2022-06-01 with a primary completion date of 2026-09-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
While the bidirectional relationship between the lung and the right heart are well studied, the cardiopulmonary interactions between the lung and the left heart are largely unresearched and not well understood. However, in recent years, there is a growing evidence that partially explains the bidirectional interaction between COPD and left heart. Systemic inflammation with multiorgan involvement is thought to play a role in COPD as a systemic disease. Some therapeutic approaches to COPD also appear to influence these cardiopulmonary interactions. While understanding these interactions is very important for clinicians, scientific data are scarce. Cardiac magnetic resonance imaging (cardiac MRI) is the gold standard for assessing cardiac function and dimensions as well as myocardial inflammation. Despite this excellent suitability of cardiac MRI for the assessment of cardiovascular function, only few studies have investigated cardiac function and myocardial structure in patients with pulmonary disease using cardiac MRI. Such a study is therefore very important for understanding the effects of pulmonary disease and its management on the heart. The objective is to determine cardiac function in patients with pulmonary disease and to analyze the cardiovascular effects of the treatment of the pulmonary disease. Specifically, the following will be studied: * Using cardiac MRI: Cardiac function and volumes and indications of myocardial fibrosis and edema in patients with chronic pulmonary disease at the time of first diagnosis. * the vascular function of pulmonary arteries in these patients, also using cardiac MRI * the relationship between pulmonary function parameters and cardiac dysfunction to identify patients at increased risk, if applicable. * Echocardiographic assessment of left heart including strain analysis. * the course of these cardiovascular parameters (using cardiac MRI and echocardiography) 3-6 months after initiation of guideline-based therapy for pulmonary disease.
Eligibility Criteria
Inclusion Criteria: * Patients with chronic lung disease requiring treatment (COPD, asthma, or pulmonary fibrosis). * Age \> 18 years * Informed consent to participate in the study will sign Exclusion Criteria: * Individuals who are not fully capable of giving consent and understanding the nature, significance and scope of the study. * Patients with contraindications to MRI examination (eg, pacemaker, severe claustrophobia) or to contrast medium use (severe renal insufficiency or glomerular filtration rate \<30 ml/min, known gadolinium contrast medium allergy) * Patients with atrial fibrillation or other significant cardiac arrhythmias that interfere with cardiac MRI * Pregnancy and lactation
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05042219 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying COPD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05042219 currently recruiting?
Yes, NCT05042219 is actively recruiting participants. Contact the research team at adaher@ukaachen.de for enrollment information.
Where is the NCT05042219 trial being conducted?
This trial is being conducted at Aachen, Germany.
Who is sponsoring the NCT05042219 clinical trial?
NCT05042219 is sponsored by Ayham Daher. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.